AT1R was targeted by losartan, which was the first angiotensin-II receptor blocker (ARB) to be approved for the treatment of hypertension in the late 1990s, and it was quickly followed by candesartan, irbesartan, valsartan, telmisartan and olmesartan [5]. This evidence concerns the gene AGTR1 and Hypertension.